Alzamend Neuro (ALZN) investor relations material

Executive summary

• Focused on developing AL001 and ALZN002 for Alzheimer's, BD, MDD, and PTSD, with both candidates in clinical stages and no product revenue to date.

• Completed Phase IIA and brain imaging studies for AL001, showing bioequivalence and superior brain penetration compared to lithium carbonate.

• Initiated Phase II clinical trial for AL001 in BD, with topline data expected in Q4 2026; MDD and PTSD trials to start Q4 2026, Alzheimer's in Q1 2027.

• ALZN002 Phase I/IIA trial delayed due to CRO termination; restart expected in Q2 2027.

Financial highlights

• No revenue generated for the three months ended July 31, 2026 or 2025.

• Net loss of $3.0 million for the quarter, up 12% year-over-year from $2.7 million.

• Operating expenses increased 12% year-over-year to $3.0 million, driven by higher general and administrative costs.

• Cash balance of $7.6 million as of July 31, 2026, up from $710,689 at April 30, 2026, due to equity financing.

Outlook and guidance

• Expects to continue incurring net losses and will require additional capital to fund operations and clinical trials.

• Plans to seek further funding through equity and debt financings; failure to secure funding may delay or halt R&D programs.

• Full pharmacokinetic and pharmacodynamic results for AL001 expected in Q4 2026.